Nature Communications (Apr 2017)
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- Xiaohong Zhao,
- Tint Lwin,
- Ariosto Silva,
- Bijal Shah,
- Jiangchuan Tao,
- Bin Fang,
- Liang Zhang,
- Kai Fu,
- Chengfeng Bi,
- Jiannong Li,
- Huijuan Jiang,
- Mark B. Meads,
- Timothy Jacobson,
- Maria Silva,
- Allison Distler,
- Lancia Darville,
- Ling Zhang,
- Ying Han,
- Dmitri Rebatchouk,
- Maurizio Di Liberto,
- Lynn C. Moscinski,
- John M. Koomen,
- William S. Dalton,
- Kenneth H. Shain,
- Michael Wang,
- Eduardo Sotomayor,
- Jianguo Tao
Affiliations
- Xiaohong Zhao
- Departments of Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center
- Tint Lwin
- Departments of Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center
- Ariosto Silva
- Department of Cancer Imaging and Metabolism
- Bijal Shah
- Department of Malignant Hematology, Moffitt Cancer Center
- Jiangchuan Tao
- Department of Laboratory Medicine and Hematopathology, Moffitt Cancer Center
- Bin Fang
- Proteomics Core Facility, Moffitt Cancer Center
- Liang Zhang
- Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center
- Kai Fu
- Department of Pathology, University of Nebraska Medical Center
- Chengfeng Bi
- Department of Pathology, University of Nebraska Medical Center
- Jiannong Li
- Biostatistics Core Facility, Moffitt Cancer Center
- Huijuan Jiang
- Department of Hematology, Tianjin Medical University General Hospital
- Mark B. Meads
- Department of Malignant Hematology, Moffitt Cancer Center
- Timothy Jacobson
- Department of Cancer Imaging and Metabolism
- Maria Silva
- Department of Cancer Imaging and Metabolism
- Allison Distler
- Department of Malignant Hematology, Moffitt Cancer Center
- Lancia Darville
- Proteomics Core Facility, Moffitt Cancer Center
- Ling Zhang
- Departments of Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center
- Ying Han
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory
- Dmitri Rebatchouk
- nPharmakon LLC
- Maurizio Di Liberto
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Lynn C. Moscinski
- Department of Laboratory Medicine and Hematopathology, Moffitt Cancer Center
- John M. Koomen
- Departments of Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center
- William S. Dalton
- Department of Malignant Hematology, Moffitt Cancer Center
- Kenneth H. Shain
- Departments of Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center
- Michael Wang
- Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center
- Eduardo Sotomayor
- Department of Hematology & Oncology, George Washington University
- Jianguo Tao
- Departments of Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center
- DOI
- https://doi.org/10.1038/ncomms14920
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
Ibrutinib has demonstrated high response rates in B-cell lymphomas but a lot of ibrutinib-treated patients relapse with resistance. This study unified TME-mediatedde novoand acquired drug resistance through B-cell receptor signalling and PI3K-AKT-mTOR axis and provides a combination therapeutic strategy against B-cell malignancies.
